Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To determine if adjunctive N-acetylcysteine 1200 mg twice a day (BID) accelerates sputum
culture conversion and normalization of cellular glutathione in tuberculosis (TB), and to
assess its potential effects on lung and immune function